As tumor progression increases TME complexity,34,35 single-agent therapy becomes insufficient.36,37 Hence, combination strategies or early interventions may be necessary for effectively targeting the IL-1β–LCN2 axis. This evidence concerns the gene LCN2 and neoplasm.